Posted:
Regeneron Pharmaceuticals reported that its experimental gene therapy, DB-OTO, demonstrated improved hearing in 10 out of 11 children aged between 10 months and 16 years who were born with hearing loss due to mutations in the OTOF gene.
Among five patients assessed at 24 weeks post-treatment, three exhibited hearing improvements to “nearly normal” or “normal” levels. This gene therapy delivers DNA instructions to inner ear cells to produce the otoferlin protein, which is essential for transmitting sound signals to the brain.
The findings were presented at the Association for Research in Otolaryngology’s 48th Annual MidWinter Meeting. Read more here: https://www.fiercebiotech.com/biotech/regenerons-gene-therapy-improves-hearing-11-children-rare-hearing-loss-disease
